Philippe Pouletty is a co-founder and CEO of TRUFFLE CAPITAL, one of Europe’s leading venture capital firms that recently announced the successful raise of € 400M from institutional investors, CEO of NAKOSTECH SARL and CEO of SC NAKOSTECH.
A pioneer in the biotechnology and medical device industry, he has decades of experience both in France and in Silicon Valley.
Philippe holds several positions at Truffle Capital portfolio companies: he is a co-founder and member of the board of directors of Carmat (Euronext: ALCAR), Carbios and Pharnext (Euronext: ALPHA), founder and member of the boards of directors of Deinove (Euronext ALDEI), Carbios (Euronext ALCRB). Founder and chairman of Abivax (Euronext: ABVX) and Diaccurate, founder and a member of the board of directors of Affluent Medical, Holistick Medical, Artedrone, Skinosive.
As an inventor, Philippe has filed more than 30 patents, one of which is the second-highest revenue generator in life sciences for Stanford University, earning him membership in Stanford’s prestigious Invention Hall of Fame in 2012. In 1988, he founded SangStat (immunotherapeutics), which was listed on Nasdaq in 1993 and sold to Genzyme for $600 million in 2002. He founded Conjuchem in 1993, which was listed on the Toronto Stock Exchange in 2000.
Philippe was Chairman of France Biotech, the French biotech industry association, from 2001 to 2009 and has held the title of Honorary Chairman since 2009. He conceived the Jeune Entreprise Innovante (JEI) status to boost the development of young and innovative companies in France, which was implemented by President Jacques Chirac in 2004 and has recently been named by the European Commission as the best tax incentive of its kind in the EU. He also served as vice-chairman of Europabio, the European biotech industry association.
A former resident (interne des Hôpitaux de Paris) in hematology and immunology in Paris hospitals, Philippe received his Medical Doctor degree from Paris VI University, graduated from Institut Pasteur in immunology and virology, performed research as a postdoctoral fellow at Hôpital Saint-Louis and Stanford University, and was the winner of an award from the American Liver Foundation in 1999. He was named Chevalier de la Légion d’Honneur by the French government in 2002.
CARANX MEDICAL 